A randomized trial of somatostatin to regulate the VEGFs/VEGFRs in patients with gastric cancer

Hepato-Gastroenterology

Volumn 58, Issue 109, 2011, Pages 1425-1430

  Zhao, Bin ^a   Yang, Peimin ^a   Yang, Jing ^a   Cai, Duan ^b  

^a Shanghai 7th People's Hospital   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Gastric cancer; Somatostatin; Vascular endothelial growth factor; VEGF receptors

Indexed keywords

SOMATOSTATIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADULT; ANGIOGENESIS; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; RANDOMIZED CONTROLLED TRIAL; RECEPTOR DOWN REGULATION; STOMACH CANCER; TOTAL STOMACH RESECTION; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SOMATOSTATIN; STOMACH NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 83355172708     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge10749     Document Type: Article

References (32)

1. "Cancer (Fact sheet No297)". World Health Organization. 2009.
2. Coultas L, Chawengsaksophak K, Rossant J: Endothelial cells and VEGF in vascular development. Nature 2005; 438:937-945. (Pubitemid 43093959)
3. Werther K, Christensen IJ, Brünner N, Nielsen HJ: Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma. The Danish RANX05 Colorectal Cancer Study Group. Eur J Surg Oncol 2000; 26:657-662.
4. Seo Y, Baba H, Fukuda T, Takashima M, Sugimachi K: High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 2000; 88:2239-2245. (Pubitemid 30247122)
5. Ikeda N, Adachi M, Taki T, Huang C, Hashida H, Takabayashi A, Sho M, Nakajima Y, Kanehiro H, Hisanaga M, Nakano H, Miyake M: Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer 1999; 79:1553-1563. (Pubitemid 29116820)
6. Claudio PP, Russo G, Kumar CA, Minimo C, Farina A, Tutton S, Nuzzo G, Giuliante F, Angeloni G, Maria V, Vecchio FM, Campli CD, Giordano A: pRb2/p130, vascular endothelial growth factor, p27(KIP1), and proliferating cell nuclear antigen expression in hepatocellular carcinoma: their clinical significance. Clin Cancer Res 2004; 10:3509-3517. (Pubitemid 38685460)
7. Erenoglu C, Akin ML, Uluutku H, Tezcan L, Yildirim S, Batkin A: Angiogenesis predicts poor prognosis in gastric carcinoma. Dig Surg 2000; 17:581-586. (Pubitemid 32045993)
8. Kolev Y, Uetake H, Iida S, Ishikawa T, Kawano T, Sugihara K: Prognostic significance of VEGF expression in correlation with COX-2, microvessel density, and clinicopathological characteristics in human gastric carcinoma. Ann Surg Oncol 2007; 14:2738-2747. (Pubitemid 47460647)
9. Eroǧlu A, Demirci S, Ayyildiz A, Kocaoǧlu H, Akbulut H, Akgül H, Elhan HA: Serum concentrations of vascular endothelial growth factor and nitrite as an estimate of in vivo nitric oxide in patients with gastric cancer. Br J Cancer 1999; 80:1630-1634. (Pubitemid 29308647)
10. Karayiannakis A, Syrigos KN, Polychronidis A: Circulating VEGF levels in the serum of gastric cancer patients. Ann Surg 2002; 236: 37-42.
11. Poulsen JE: Recovery from retinopathy in a case of diabetes with Simmonds' disease. Diabetes 1953; 2: 7-12.
12. Hofland LJ and Lamberts SW: Somatostatin receptor subtype expression in human tumors. Ann Oncol 2001; 12 (Suppl. 2):S31-S36. (Pubitemid 33069684)
13. de Herder WW and Lamberts SW: Somatostatin and somatostatin analogues: diagnostic and therapeutic uses. Curr Opin Oncol 2002; 14:53-57.
14. Melmed S, Vance ML, Barkan AL, Bengtsson BA, Kleinberg D, Klibanski A, Trainer PJ: Current status and future opportunities for controlling acromegaly. Pituitary 2002; 5:185-196. (Pubitemid 36656432)
15. Mentlein R, Eichler O, Forstreuter F, Held-Feindt J: Somatostatin Somatostatin inhibits the production of vascular endothelial growth factor in human glioma cells. Int J Cancer 2001; 92:545-550. (Pubitemid 32319428)
16. Woltering EA: Development of targeted somatostatin-based antiangiogenic therapy: a review and future perspetive. Cancer Biother Radiopharm 2003; 18:601-609.
17. Woltering EA, Barrie R, O'Dorisio TM, Arce D, Ure T, Cramer A, Holmes D, Robertson J, Fassler J: Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane. J Surg Res 1991; 50:245-251.
18. Woltering EA, Watson JC, Alperin-Lea RC, Sharma C, Keenan E, Kurozawa D, Barrie R: Somatostatin analogs: angiogenesis inhibitors with novel mechanisms of action. Invest New Drugs 1997; 15:77-86. (Pubitemid 27217753)
19. Barrie R, Woltering EA, Hajarizadeh H, Mueller C, Ure T, Fletcher WS: Inhibition of angiogenesis by somatostatin and somatostatin-like compounds is structurally dependent. J Surg Res 1993; 55:446-450.
20. Eroglu A, Demirci S, Ayyildiz A: Serum concentrations of vascular endothelial growth factor and nitrite as an estimate of in vivo nitric oxide in patients with gastric cancer. Br J Cancer 1999; 80:1630-1634. (Pubitemid 29308647)
21. Karayiannakis A, Syrigos KN, Polychronidis A: Circulating VEGF levels in the serum of gastric cancer patients. Ann Surg 2002; 236:37-42.
22. Mentlein R, Eichler O, Forstreuter F, Held-Feindt J: Somatostatin inhibits the production of vascular endothelial growth factor in human glioma cells. Int J Cancer 2001; 15;92(4):545-50.
23. Barrie R, Woltering EA, Hajarizadeh H, Mueller C, Ure T, Fletcher WS: Inhibition of angiogenesis by somatostatin and somatostatin-hke compounds is structurally dependent. J Surg Res 1993; 55(4):446-50.
24. Brostjan C, Bayer A, Zommer A, Gornikiewicz A, Roka S, Benkö T, Yaghubian R, Jakesz R, Steger G, Gnant M, Friedl J, Stift A: Monitoring of circulating angiogenic factors in dendritic cell-based cancer immunotherapy. Cancer 2003; Nov 15; 98(10):2291-301.
25. Norden-Zfoni A, Desai J, Manola J, Beaudry P, Force J, Maki R, Folkman J, Bello C, Baum C, DePrimo SE, Shalinsky DR, Demetri GD, Heymach JV: Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 2007; May 1; 13(9):2643-50.
26. Larcher F, Murillas R, Bolontrade M, Conti CJ, Jorcano JL: VEGFATF overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor development. Oncogene 1998; 17:303-311. (Pubitemid 28383007)
27. Larcher F, Robles AI, Duran H, Murillas R, Quintanilla M, Cano A, Conti CJ, Jorcano JL: Up-regulation of vascular endothelial growth factor/vascular permeability factor in mouse skin carcinogenesis correlates with malignant progression state and activated H-ras expression levels. Cancer Res 1996; 1;56(23):5391-6.
28. Casanova ML, Larcher F, Casanova B, Murillas R, Fernández- Aceñero MJ, Villanueva C, Martínez-Palacio J, Ullrich A, Conti CJ, Jorcano JL: A critical role for ras-mediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin carcinogenesis. Cancer Res 2002; 15;62(12):3402-7.
29. Drevs J, Siegert P, Medinger M, Mross K, Strecker R, Zirrgiebel U, Harder J, Blum H, Robertson J, Jürgensmeier JM, Puchalski TA, Young H, Saunders O, Unger C: Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007; 25(21):3045-54. (Pubitemid 47218051)
30. Drevs J: Soluble markers for the detection of hypoxia under antiangiogenic treatment. Anticancer Research 2003; 23(2A):1159-1161.
31. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349(5):427-34. (Pubitemid 36910021)
32. Yonemura Y, Fushida S, Bando E, Kinoshita K, Miwa K, Endo Y, Sugiyama K, Partanen T, Yamamoto H, Sasaki T: Lymphangiogenesis and the vascular endothelial growth factor receptor (VEGFR)-3 in gastric cancer. Eur J Cancer 2001; 37(7):918-23. (Pubitemid 32323971)